Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine

Intern Med. 2017;56(3):335-339. doi: 10.2169/internalmedicine.56.7010. Epub 2017 Feb 1.

Abstract

The patient was 32-year-old man, who received olanzapine for schizophrenia and developed polyuria and thirst without drinking soft-drinks after 4 months. Five months after the initiation of treatment, he developed diabetic ketoacidosis (blood glucose: 490 mg/dL, HbA1c: 15.5%). He was diagnosed with type 1 diabetes (glutamic acid decarboxylase (GAD)-Ab: 5.6 U/mL, IA-2 Ab: 5.9 U/mL, fasting C-peptide: 0.12 ng/mL) and was put on intensive insulin therapy. At four months after the onset of 1A diabetes, he experienced a honeymoon phase that was sustained until the 40th month of treatment. We hypothesize that the administration of olanzapine to a patient with pre-type 1A diabetes induced marked hyperglycemia and accelerated the onset of type 1A diabetes.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antipsychotic Agents / adverse effects*
  • Benzodiazepines / administration & dosage
  • Benzodiazepines / adverse effects*
  • Blood Glucose
  • Diabetes Mellitus, Type 1 / diagnosis*
  • Diabetes Mellitus, Type 1 / physiopathology
  • Diabetic Ketoacidosis / chemically induced
  • Diabetic Ketoacidosis / drug therapy
  • Humans
  • Hyperglycemia / chemically induced*
  • Hyperglycemia / drug therapy
  • Insulin / therapeutic use
  • Male
  • Olanzapine
  • Prediabetic State / complications
  • Prediabetic State / diagnosis*
  • Schizophrenia / drug therapy

Substances

  • Antipsychotic Agents
  • Blood Glucose
  • Insulin
  • Benzodiazepines
  • Olanzapine